Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intermittent Every Other Days of 5 Shot-filgrastim Compared With Single Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy (Intermittent G-CSF 105)

Next Previous
X
Search
Trial Profile

Intermittent Every Other Days of 5 Shot-filgrastim Compared With Single Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy (Intermittent G-CSF 105)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgrastim (Primary) ; Pegfilgrastim
  • Indications Febrile neutropenia
  • Focus Therapeutic Use

    • Most Recent Events

    • 29 Jul 2020 Status changed from recruiting to discontinued.
    • 15 Nov 2019 Due to funding issues the study period only spanned the first 3 cycles of adjuvant chemotherapy and could not cover the whole 6 cycles as originally planned as per an article published in Investigational New Drugs
    • 15 Nov 2019 Primary endpoint (Cumulative incidence of febrile neutropenia) has not been met as per the results published in the Investigational New Drugs

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top